Acute, multiple-dose dermal and genetic toxicity of Nu-3: A novel antimicrobial agent

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Sun, L-Q
dc.contributor.author Sun, J
dc.contributor.author Hu, Y
dc.contributor.author Cao, S
dc.contributor.author Zhang, G
dc.contributor.author Wang, M
dc.date.accessioned 2011-02-07T06:23:54Z
dc.date.issued 2010
dc.identifier.citation Journal of Biomedicine and Biotechnology, 2010, 2010
dc.identifier.issn 1110-7243
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/13696
dc.description.abstract Nu-3 [butyl-phosphate- 5 ′ -thymidine- 3 ′ -phosphate-butyl] is a modified nucleotide that has been shown to have antimicrobial activity against a range of bacteria including Pseudomonas aeruginosa. However, data on the toxicological profile of Nu-3 are still lacking. In the present study, the toxicity of Nu-3 was evaluated by the following studies: acute oral toxicity, dermal and mucous membrane irritation, multiple-dose toxicity and genotoxicity in vivo and vitro. The acute oral toxicity test in mice showed that Nu-3 had an LD 50 of 2001mg/kg body weight. The irritation tests on rats revealed that Nu-3 was not irritant, with an irritation scoring of 0. The multiple-dose toxicity study in rats showed that Nu-3 did not cause significant changes in histology, selected serum chemistry, and hematological parameters compared to the controls. Rats administrated with multiple-doses of Nu-3 showed no visible toxic symptoms. Both in vitro and in vivo, Nu-3 exhibited no notable genetic toxicity. Overall, the data suggest that Nu-3 is hypotoxic or nontoxic antimicrobial compound that warrants being further developed for treating Pseudomonas aeruginosa infection. © 2010 Juan Sun et al.
dc.language eng
dc.relation.isbasedon 10.1155/2010/362524
dc.title Acute, multiple-dose dermal and genetic toxicity of Nu-3: A novel antimicrobial agent
dc.type Journal Article
dc.parent Journal of Biomedicine and Biotechnology
dc.journal.volume 2010
dc.publocation New York en_US
dc.publocation Denmark
dc.identifier.startpage 1 en_US
dc.identifier.endpage 8 en_US
dc.cauo.name FEIT.School of Systems, Management and Leadership en_US
dc.conference Verified OK en_US
dc.for 1004 Medical Biotechnology
dc.personcode 020014
dc.personcode 104335
dc.percentage 100 en_US
dc.classification.name Medical Biotechnology en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.edition 1st
dc.custom en_US
dc.date.activity en_US
dc.location.activity ISI:000281300400001 en_US
dc.location.activity ISI:000281300400001
dc.description.keywords Cho-Hgprt System; Resistant Pseudomonas-Aeruginosa; Intensive-Care Units; Beta-Lactamase; Burn Unit; Outbreak; Assay en_US
dc.description.keywords Three Time-Zone (3TZ), Virtual Student Exchange (VSX), Collaborative Environment, Group Project Management, On-Demand Virtual Labs (ODVL)
dc.description.keywords Cho-Hgprt System
dc.description.keywords Resistant Pseudomonas-Aeruginosa
dc.description.keywords Intensive-Care Units
dc.description.keywords Beta-Lactamase
dc.description.keywords Burn Unit
dc.description.keywords Outbreak
dc.description.keywords Assay
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group /University of Technology Sydney/Faculty of Science
pubs.organisational-group /University of Technology Sydney/Strength - Quantum Computation and Intelligent Systems
utslib.copyright.status Open Access
utslib.copyright.date 2015-04-15 12:23:47.074767+10


Files in this item

This item appears in the following Collection(s)

Show simple item record